Multiplexed assay for point-of-care UTI diagnosis (ID/AMR)
Active Project Grant Awarded Last action
- Award ID
- R44AI181154
- Recipient
-
Nanopath Inc. UEI MURFWBMTD7F7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,878,252
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 89% complete
- Place of performance
- Cambridge, MA 02139, USA
Award details come from USAspending.gov.
Description
- Abstract
- Nanopath proposes to develop a point-of-care molecular diagnostic that can identify UTI-causing pathogens and key genetic markers of antibiotic resistance directly from a patient urine sample in 15 minutes, without the need for nucleic acid amplification. Despite the severity and prevalence of utis, the current diagnostic standard-of-care relies on culture-based methods, which take an average several days to return species-level and antimicrobial resistance information. This time- intensive diagnostic workflow leaves many patients in pain and/or at-risk of severe infection before they are prescribed targeted antibiotic therapy. Critically, empiric treatment of utis is one of the largest contributors to the growing problem of antibiotic resistance. Nanopath's product is a single- use assay cartridge coupled to a low-cost readout instrument. The assay cartridge integrates sample preparation with our proprietary molecular nanosensor. Our multiplexed molecular nanosensor is functionalized with an array of probes complementary to 1) species-specific genetic sequences and 2) genetic markers of antimicrobial resistance. In our preliminary work, we designed a 5-target proof-of-concept panel encompassing three bacterial species and two antimicrobial resistance genes that are commonly observed in utis. Our preliminary data demonstrate highly selective and robust target detection in a variety of sample matrices, including healthy patient urine. Our phase II effort will focus on four specific aims. First, we will expand our target panel to encompass >95% of UTI-causing organisms and key markers of antimicrobial resistance. This will involve rational design and bench-top validation of candidate PNA probes to inform a finalized panel and probe set. Second, we will optimize the design of the assay cartridge to integrate sample handling functions, lower limit-of-detection, and enable high throughput sample processing. This aim will also support low-volume manufacturing of the assay cartridge in preparation for verification studies. Third, we will perform a series of comprehensive analytical verification studies on the assay. Finally, we will characterize clinical performance of nanopath's UTI assay in pilot clinical study (N>200) in collaboration with brigham & women's hospital. Successful commercialization of this technology will enable point-of-care characterization of utis in
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $919,857 | |
| Amendment | $964,943 | |
| Amendment | $996,726 | |
| Original award | $996,726 |
Quick answers
Who received award R44AI181154?
R44AI181154 was awarded to Nanopath Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 1, 2024.
How much is award R44AI181154 worth?
$3,878,252 has been obligated on R44AI181154.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award